Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Schering-Plough |
---|---|
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00654095 |
Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and atorvastatin in patients with hypercholesterolemia who have not reached LDL-cholesterol target with HMG-CoA reductase inhibitors.
Condition | Intervention | Phase |
---|---|---|
Hypercholesterolemia |
Drug: Ezetimibe Drug: atorvastatin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Open-label, Long-term Study of Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors |
Estimated Enrollment: | 140 |
Study Start Date: | December 2007 |
Study Completion Date: | June 2009 |
Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Ezetimibe + Atorvastatin: Experimental
Ezetimibe 10 mg + Atorvastatin 20 mg
|
Drug: Ezetimibe
Ezetimibe 10 mg once daily
Drug: atorvastatin
atorvastatin 20 mg once daily
|
Ages Eligible for Study: | 20 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with hypercholesterolemia who satisfy the following criteria:
Exclusion Criteria:
Patients for whom any of the following is applicable:
Patients with hyperlipidemia associated with the following diseases:
Responsible Party: | Schering-Plough ( Head, Clinical Trials Registry & Results Disclosure Group ) |
Study ID Numbers: | P05456 |
Study First Received: | April 1, 2008 |
Last Updated: | July 29, 2009 |
ClinicalTrials.gov Identifier: | NCT00654095 History of Changes |
Health Authority: | Japan: Pharmaceuticals and Medical Devices Agency |
Antimetabolites Metabolic Diseases Hyperlipidemias Antilipemic Agents Ezetimibe Anticholesteremic Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Metabolic Disorder Hypercholesterolemia Atorvastatin Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Hyperlipidemias Metabolic Diseases Molecular Mechanisms of Pharmacological Action Antilipemic Agents Enzyme Inhibitors Ezetimibe Anticholesteremic Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Therapeutic Uses Hypercholesterolemia Dyslipidemias Atorvastatin Lipid Metabolism Disorders |